试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-11
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
编号:NCT03566823登记状态:提前终止企业 / 申办者:Shire
药物 / 成分:Ontamalimab、Placebo
登记的停止原因(原文):Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-11
A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection
编号:NCT03762681登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:RO7239958、Placebo
登记的停止原因(原文):The study was terminated due to program discontinuation.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-11
A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059
编号:NCT04575818登记状态:提前终止企业 / 申办者:Lakefront Biotherapeutics NV
药物 / 成分:GLPG4059 oral suspension、Placebo、GLPG4059 tablet
登记的停止原因(原文):Development of compound has been stopped
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-11
COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study
编号:NCT04746430登记状态:提前终止企业 / 申办者:General Practitioners Research Institute
药物 / 成分:Dexamethasone
登记的停止原因(原文):Too few patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-10
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
编号:NCT00230334登记状态:提前终止企业 / 申办者:Steven E. Coutre
药物 / 成分:Gleevec
登记的停止原因(原文):terminated by PI due to insufficient accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-10
Extension Study Of Tanezumab In Osteoarthritis
编号:NCT00809783登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:tanezumab、tanezumab、tanezumab
登记的停止原因(原文):See termination reason in detailed description.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-10
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
编号:NCT02805894登记状态:提前终止企业 / 申办者:Nanobiotix
药物 / 成分:NBTXR3 activated by IMRT only、NBTXR3 activated by Brachytherapy & IMRT
登记的停止原因(原文):Prostate cancer treatment has greatly changed since the initiation of this trial and therefore we have stopped this trial to allow for further evaluation of the treatment landscape
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-10
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
编号:NCT03478904登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Enzalutamide Liquid、Enzalutamide Capsule
登记的停止原因(原文):Study drug is now commercially available in tablet format
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-10
Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone
编号:NCT03658109登记状态:提前终止企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Lidocaine Bolus Infusion、QL block、Saline Bolus Infusion、Simulated QL block
登记的停止原因(原文):Recruitment challenges due to COVID-19
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-07
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
编号:NCT02080364登记状态:提前终止企业 / 申办者:vTv Therapeutics
药物 / 成分:Azeliragon、Placebo
登记的停止原因(原文):Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.
查看官方原始记录 ↗